Last reviewed · How we verify
Colchicine only
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and activation.
Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and activation. Used for Acute gout flare prophylaxis and treatment, Familial Mediterranean fever, Cardiovascular disease (post-myocardial infarction, atherosclerosis) — Phase 3 investigation.
At a glance
| Generic name | Colchicine only |
|---|---|
| Sponsor | The George Institute |
| Drug class | Microtubule inhibitor / Anti-inflammatory agent |
| Target | β-tubulin |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Immunology / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Colchicine binds to β-tubulin and prevents microtubule assembly, which disrupts cell division and inflammatory cell movement. This leads to reduced recruitment of neutrophils and other immune cells to sites of inflammation, and decreases the production of inflammatory mediators like IL-1β and TNF-α. The drug has been used for decades in gout and is now being investigated for cardiovascular and other inflammatory indications.
Approved indications
- Acute gout flare prophylaxis and treatment
- Familial Mediterranean fever
- Cardiovascular disease (post-myocardial infarction, atherosclerosis) — Phase 3 investigation
Common side effects
- Diarrhea
- Nausea
- Abdominal pain
- Myopathy
- Peripheral neuropathy
Key clinical trials
- Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant (PHASE4)
- Colchicine Treatment for Non-Flow-Limiting Coronary Plaque by Coronary CTA: A Randomized Controlled Trial (PHASE4)
- Pilot Trial of Colchicine for Graft Failure in CABG (PHASE4)
- Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias (PHASE4)
- Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout (PHASE4)
- EFFICACY OF COLCHICINE IN IMPROVING CLINICAL OUTCOMES IN PATIENTS WITH MILD TO MODERATE COVID-19 PNEUMONIA IN LAHORE: A RANDOMIZED CONTROL TRIAL (PHASE1, PHASE2)
- Outcomes of Inspiratory Muscle Training in FMF Adolescents (NA)
- Perioperative Colchicine for TKA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |